賽升藥業(300485.SZ):子公司賽而生物通過高新技術企業認定
格隆匯1月13日丨賽升藥業(300485.SZ)公佈,公司的子公司北京賽而生物藥業有限公司(簡稱“賽而生物”)於近日收到北京市科學技術委員會、北京市財政局、國家税務總局北京市税務局聯合頒發的《高新技術企業證書》,賽而生物通過高新技術企業認定,高新技術企業證書編號為GR202211003428,發證日期為2022年12月1日,有效期為三年。
根據國家對高新技術企業税收優惠政策的相關規定,賽而生物自該次通過高新技術企業認定當年起三年內(即2022年度、2023年度、2024年度)可享受國家關於高新技術企業所得税優惠政策,即按15%的税率繳納企業所得税。該次通過高新技術企業認定事項不會對公司當期經營業績產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.